Articles for tag: aandeel sanofi, Acquisition, acquisition of biotechnology, Acquisition Sanofi, acquisitions of drugs, action stellantis, Actions sanofi, AGRICOLE Credit Action, Arsenal, Atos action, Ayvakit, biotechnology, biotechnology news, biotechnology offers, Blu-808, blueprint, BluePrint Stock, Bnp bourse, Bourse air liquide, bourse direct, Bourse saint gobain, Bourse sanofi, Bourse stellantis, Bourse Thales, Bourse vallourec, Cac 40, Cac 40 sanofi, Cac40, cause alstom, clinical trials, Cours Airbus, Development, Draft, drug approval, drug conductor, drugs, enhances, exclusive, Health Care Mergers, healthcare industry, immunology, immunology drugs, Investment in US pharmacies, lavish, LVMH action, Lyon, manufacture, Medical discoveries, Mountain, News of Biotechnology Industry, of the drug, Opella sanofi, Paul Hudson, pharmaceutical, pharmaceutical industry, pharmaceutical innovation, pharmaceutical market, Pharmaceutical news, Pharmaceutical R&D, pharmaceutical strategy, Pharmaceuticals, portfolio, rare diseases, rarely, rarely immunology, Rarely treatment of diseases, reserves of biotechnology, Sanofi action, Sanofi Aktie, Sanofi aventis, Sanofi career, Sanofi conductor, Sanofi cours, Sanofi gentilly, Sanofi gets, Sanofi headquarters, Sanofi india, Sanofi India share price, Sanofi koers, Sanofi logo, Sanofi news, Sanofi pro, Sanofi ride, Sanofi share, Sanofi shares price, Sanofi stock price, Sanofi working day, Sanofis, Stock Exchange, Systematic Mastocytosis Therapy, systemic mastocytosis, The drugs approved by the FDA, total stock market, US Biofarm, world pharmacy

June 2, 2025

News Desk

Business

The acquisition of Sanofi’s BluePrint drugs rarely enhances portfolio immunology

In an important move, she highlights her ambition to lead to rare illnesses and immunology, the French pharmaceutical giant Sanofi announced her plan to obtain US -based BluePrint medicines for up to $ 9.5 billion. The agreement was announced by a press release on the Sanofi website. It is the largest of a European health care company this year and will see Sanofi pay $ 129 per share in cash, an important premium that sent the plan stock to go to the premarket trading. BluePrint drugs, known for its specialty in the treatment of systemic mastocytosis, a rare blood disorder